{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:48:15Z","timestamp":1740138495242,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12032-021-01489-8","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T03:02:44Z","timestamp":1616209364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of thoracic radiation in extensive stage small cell lung cancer: a NCDB analysis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6484-2210","authenticated-orcid":false,"given":"Takefumi","family":"Komiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinkichi","family":"Takamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"1489_CR1","unstructured":"American Cancer Society. Lung cancer survival rates. American Cancer Society. https:\/\/www.cancer.org\/cancer\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed 17 Mar 2021."},{"key":"1489_CR2","unstructured":"National Cancer Institute. Small cell lung cancer treatment (PDQ\u00ae)-health professional version. National Cancer Institute. https:\/\/www.cancer.gov\/types\/lung\/hp\/small-cell-lung-treatment-pdq#link\/_37. Accessed 17 Mar 2021."},{"key":"1489_CR3","unstructured":"NCCN clinical practice guidelines in oncology. Small cell lung cancer. Version 1.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Accessed 17 Mar 2021."},{"key":"1489_CR4","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","volume":"20","author":"M Takada","year":"2002","unstructured":"Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054\u201360.","journal-title":"J Clin Oncol"},{"key":"1489_CR5","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1200\/JCO.2004.01.178","volume":"22","author":"DB Fried","year":"2004","unstructured":"Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22:4837\u201345.","journal-title":"J Clin Oncol"},{"key":"1489_CR6","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.1999.17.7.2092","volume":"17","author":"B Jeremic","year":"1999","unstructured":"Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17:2092\u20139.","journal-title":"J Clin Oncol"},{"key":"1489_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36\u201342.","journal-title":"Lancet"},{"key":"1489_CR8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","volume":"12","author":"EM Gore","year":"2017","unstructured":"Gore EM, Hu C, Sun AY, et al. Randomized Phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017;12:1561\u201370.","journal-title":"J Thorac Oncol"},{"key":"1489_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2017.03.007","volume":"108","author":"BJ Slotman","year":"2017","unstructured":"Slotman BJ, Faivre-Finn C, van Tinteren H, et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the Phase III CREST trial. Lung Cancer. 2017;108:150\u20133.","journal-title":"Lung Cancer"},{"key":"1489_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"2","author":"P Goldstraw","year":"2007","unstructured":"Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007;2:706\u201314.","journal-title":"J Thorac Oncol"},{"key":"1489_CR11","doi-asserted-by":"crossref","unstructured":"Rami-Porta R, Bolejack V, Giroux DJ, et al. International Association for the Study of Lung Cancer Staging, Prognostic Factors Committee ABM, Participating Institutions. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2014;9:1618\u201324.","DOI":"10.1097\/JTO.0000000000000334"},{"key":"1489_CR12","unstructured":"American College of Surgeons. National Cancer Database. American College of Surgeons. https:\/\/www.facs.org\/quality-programs\/cancer\/ncdb. Accessed 17 Mar 2021."},{"key":"1489_CR13","unstructured":"National Cancer Institute. Morphology and Grade. ICD-O-3 Morphology Codes. https:\/\/training.seer.cancer.gov\/lung\/abstract-code-stage\/morphology.html#:~:text=ICD%2DO%2D3%20Morphology%20Codes&text=Small%20cell%20cancers%20are%20usually,treated%20as%20small%20cell%20cancers."},{"key":"1489_CR14","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. https:\/\/seer.cancer.gov\/. Accessed 17 Mar 2021."},{"key":"1489_CR15","unstructured":"National Cancer Institute. SEER Stat Software. National Cancer Institute. https:\/\/seer.cancer.gov\/seerstat\/. Accessed 17 Mar 2021."},{"key":"1489_CR16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1080\/01621459.1989.10478868","volume":"84","author":"PR Rosenbaum","year":"1989","unstructured":"Rosenbaum PR. Optimal matching for observational studies. J Am Stat Assoc. 1989;84:1024\u201332.","journal-title":"J Am Stat Assoc"},{"key":"1489_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJM199908123410703","volume":"341","author":"A Aup\u00e9rin","year":"1999","unstructured":"Aup\u00e9rin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476\u201384.","journal-title":"N Engl J Med"},{"key":"1489_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","volume":"18","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663\u201371.","journal-title":"Lancet Oncol"},{"key":"1489_CR19","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139.","journal-title":"N Engl J Med"},{"key":"1489_CR20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339.","journal-title":"Lancet"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01489-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-021-01489-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01489-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T02:10:49Z","timestamp":1617329449000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-021-01489-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01489-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"23 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TK received travel fees from Merck and Boehringer Ingelheim. All other authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed by the Institutional Review Board at Parkview Health and was designated exempt from human subject research prior to beginning data analysis","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"44"}}